FGF19 Overexpression

CI-VAR-00003194Explore in graph →CIViC 2784

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma3
FGF19 Overexpression	FGFR4 Inhibitor H3B-6527	Predictive	D	Supports Sensitivity Response	3	submitted	EID7518 In a study with a panel of 40 HCC cell lines and 30 HCC PDX model showed that FGF19 expression is a predictive biomarker for H3B-6527. H3B-6527 is a highly selective covalent FGFR4 inhibitor. PMID 29247039 · Joshi et al., 2017 · Open in CIViC	civic
FGF19 Overexpression	Fisogatinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID7636 In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once … (full text at CIViC) PMID 31575541 · Kim et al., 2019 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Ovarian Neoplasm1
FGF19 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID7523 In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC) PMID 26323668 · Hu et al., 2015 · Open in CIViC	civic